Abstract: Particulate hydroperoxidized poly-N-vinyl lactam containing an average of about 0.5 to 20 hydroperoxy mole equivalents per mole of poly-N-vinyl lactam, the preparation of the same by subjecting particulate poly-N-vinyl lactam to an effective amount of ozone, and the use thereof in the preparation of graft copolymers possessing a low degree of extractibles, finding utility in a wide number of fields, particularly in biomedical devices, semipermeable membranes, and as films or fibers.

Abstract: Novel Substituted tetrahydro-, hexahydro- and octahydro-[3,4'-bi-2H-pyrrolel]-2,2'-diones of the formula ##STR1## in which each of R.sub.1 and R.sub.

Abstract: 1-phenyl-lower alkyl-1H-1,2,3-triazole compounds of the formula ##STR1## in which Ph represents phenyl substituted by up to and including 3 substituents selected from lower alkyl, halogen and trifluoromethyl, alk represents lower alkylidene, and wherein eitherR.sub.1 represents hydrogen, lower alkyl, lower alkoxy, amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, carbamoyl, N-lower alkanoylcarbamoyl, N-lower alkylcarbamoyl or N,N-di-lower alkylcarbamoyl andR.sub.2 represents carbamoyl, N-lower alkanoylcarbamoyl, N-lower alkylcarbamoyl or N,N-di-lower alkylcarbamoyl orR.sub.1 represents carbamoyl, N-lower alkanoylcarbamoyl, N-lower alkylcarbamoyl or N,N-di-lower alkylcarbamoyl andR.sub.2 represents hydrogen or lower alkyl,have anti-convulsive properties and can be used as medicaments.

Abstract: Described are phosphatidyl compounds of the formula I ##STR1## in which R.sup.1 represents C.sub.3-14 -alkanoyl, benzoyl, the acyl radical of an .alpha.-aminocarboxylic acid that is other than glycine, L-alanine and derivatives thereof having a substituted amino group, and of which the .alpha.-amino group may be substituted by lower alkanoyl, lower alkoxycarbonyl or by benzyloxycarbonyl, or the acyl radical of a .beta.-aminocarboxylic acid or an .alpha.- or .beta.-hydroxycarboxylic acid,T represents a group NH that is unsubstituted or is substituted by lower alkyl, or oxygen,Y represents dimethylene that is unsubstituted or is substituted by free, etherified or amidated carboxy,W represents hydrogen, andZ represents a 1,2-dihydroxyethyl, 2-hydroxyethyl or hydroxymethyl group, in which at least one of the hydroxy groups is esterified by an aliphatic C.sub.8-30 -carboxylic acid or is etherified by an aliphaticC.sub.

Abstract: A pharmaceutical preparation for controlled, sustained release of dextromethorphan comprising a polystyrene sulfonate resin which has been cross-linked with about 3% to about 10% divinyl benzene, having an average particle size of at least 48 .mu.m and less than 100 .mu.m onto which dextromethorphan has been loaded in a ratio of dextromethorphan hydrobromid to resin of about 1:3 to about 1:10 and at least one pharmaceutically acceptable adjuvant.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, independently of one another, represent hydrogen, hydroxy or halogen or are alkyl, alkoxy, alkanoyloxy, or alkanoylamino groups which are unsubstituted or substituted by alkoxy, hydroxyl, halogen, aryl, cycloalkyl, azacycloalkyl, cyano or by polyalkyleneoxy, or two or more of adjacent R.sub.1 -R.sub.4 together form one or more fused rings of 5-8 members each; R is alkylene of up to 16 carbon atoms which is unsubstituted or substituted by hydroxy, lower alkoxy, or halo and which may be interrupted by oxygen, sulfur, carboxamido, sulfonamido, aminosulfonyl, aminocarbonyl, carbonyloxy, sulfinyl, or sulfonyl; and R.sub.f is perfluoroalkyl or perfluoroalkoxyalkyl of 4 to 16 carbon atoms; or mixtures thereof. Such compounds are useful as oil soluble corrosion inhibitors.

Abstract: The invention relates to novel sulfonic acid esters of formula I ##STR1## wherein R.sup.1 is C.sub.5 -C.sub.6 cycloalkyl which is unsubstituted or substituted by C.sub.1 -C.sub.7 alkyl, unsubstituted or substituted phenyl, R.sup.2 is C.sub.1 -C.sub.7 alkyl, R.sup.3 is phenyl which is substituted by halogen or nitro, and the asterisk denotes a carbon atom that is either present in the preponderant number of molecules in the S configuration or in the preponderant number of molecules in the R configuration.These compounds can be prepared by enantio-selective reduction of 4--R.sup.1 --substituted .alpha.-oxobutyric acid compounds and subsequent conversion of the resultant .alpha.-hydroxy group into the --OSO.sub.2 --R.sup.3 group. The compounds of formula I are suitable intermediates for the preparation of ACE inhibitors or precursors thereof.

Abstract: Antiinflammatory and/or analgesic pharmaceutical preparations for topical application which contain salts of alkanecarboxylic acids, novel carboxylic acid salts and the production thereof.

Abstract: A controlled release tablet comprising(I) a core, containing as essential components(a) at least one water-soluble pharmaceutically active substance which is dispersed in a water-insoluble, non-digestible polymeric excipient, and(b) a water-insoluble polymeric substance, which is swellable under the influence of water, and(II) a coating essentially of an elastic, water-insoluble and semipermeable diffusion film of a polymer,is presented, which shows a release pattern for the active substance(s) in a programmed rate of approximately zero order.

Abstract: Novel asymmetric thioethers of the formula ##STR1## in which the general symbols have the following meanings: R.sup.0 represents hydrogen or C.sub.1-7 -alkanoyl,R.sup.1 represents C.sub.1-3 -alkyl which may be substituted by one or more halogen atoms having an atomic number of at most 17,R.sup.2 represents an aliphatic radical having from 5 to 15 carbon atoms,A represents ethylene, a single bond or vinylene,B.sup.1 represents C.sub.1-7 -alkylene or phenylene,B.sup.2 represents a single bond, ethylene or phenylene, andM represents an aromatic radical of the partial formula ##STR2## in which the symbols have the following meanings: R.sup.3 represents hydrogen or C.sub.1-4 -alkyl,X represents NH, O, S or if R.sup.4 represents hydrogen, a single bond,one of the symbols R.sup.4 and R.sup.5 represents hydrogen and the other represents the group --CO--R.sup.6, orR.sup.4 and R.sup.5 together represent the radical --CO--C(R.sup.6).dbd.C(R.sup.7)--or--CO--C(R.sup.7).dbd.C(R.sup.6)--orR.sup.4 R.sup.

Abstract: The invention relates to a new method of immunological analysis for serum amyloid A protein (SAA) and serum amyloid P-component (SAP), kits therefor and a method of purification of SAA and SAP. These methods are based on the efficient binding of SAP to a plastic surface and to carriers bearing nitrated phenyl groups in the presence of calcium and related bivalent ions, and of SAA to a plastic surface and to carriers bearing nitrated phenyl groups with or without calcium ions. The method of immunological analysis allows for rapid and reliable screening of serum samples with a high sensitivity. SAA and SAP play a key role in the diagnosis and management of inflammatory diseases.

Abstract: Contact lenses which are optically clear, wettable, flexible, of high oxygen permeability and substantially non-swellable in the aqueous ocular environment of use, of a polymer containing polyoxyalkylene backbone units are disclosed, as well as the preparation thereof and methods of treating vision defects therewith.

Abstract: A method of inhibiting cataract formation occasioned by the oxidative cross-linking of proteinaceous material in the lens fiber of the eye of a mammal comprising the topical administration of an effective antioxidant amount, to the eye of said mammal in need of the same, of a compound of the formula: ##STR1## wherein R is phenyl or phenyl substituted lower alkyl, the phenyl group of each being unsubstituted or substituted by halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro, di-loweralkylamino, cyano, carboxy, methylenedioxy, loweralkoxycarbonyl, carboxyloweralkyl, or loweralkoxycarbonyl-lower alkyl, or R is cycloalkyl of 5 to 10 carbon atoms; andR.sub.1 and R.sub.2 are independently hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, trifluoromethyl, or nitro or R.sub.1 and R.sub.2 taken together are methylenedioxy.

Abstract: A method of treating an ocular allergy in a mammal comprising the topical application of an effective anaphylactic inhibiting amount of a compound of the formula: ##STR1## wherein R is phenyl or phenyl substituted lower alkyl, the phenyl group of each being unsubstituted or substituted by halo, lower alkyl, lower alkoxy, trifluoromethyl, nitro, di-loweralkylamino, cyano, carboxy, methylenedioxy, loweralkoxycarbonyl, carboxyloweralky, or loweralkoxycarbonyl-lower alkyl, or R is cycloalkyl of 5 to 10 carbon atoms; andR.sub.1 and R.sub.2 are independently hydrogen, halo, lower alkyl, lower alkoxy, hydroxy, trifluoromethyl, or nitro or R.sub.1 and R.sub.2 taken together are methylenedioxy; to the eye of said mammal in need of the same.

Abstract: Benzamides of the formula ##STR1## in which R.sub.1 and R.sub.2, independently of one another, each represents lower alkyl, R.sub.3 represents lower alkoxy, C.sub.3 -C.sub.5 -alkenyloxy, C.sub.3 -C.sub.7 -cycloalkoxy or C.sub.3 -C.sub.7 -cycloalkyl-lower alkoxy, R.sub.4 represents halogen and R.sub.5 represents cyano, and their salts can be used, for example, as pharmaceutical agents and can be manufactured in a manner known per se.

Abstract: The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof.These compounds have valuable pharmaceutical properties.

Abstract: A method of reducing a viscosity of asphaltenic crude oils by incorporating into said crude oil an effective viscosity reducing amount of an oil soluble organic compound having at least one oleophobic and hydrophobic fluoroaliphatic group, and optionally a low viscosity diluent, and compositions thereof.

Abstract: A method of inhibiting the deposition of paraffin wax, asphaltene, or mixtures thereof in a crude oil contaminated with paraffin wax, asphaltene, or mixtures thereof and susceptible to such depositions comprising the step of incorporating into said crude oil an effective deposition inhibiting amount of an oil soluble organic compound having at least one oleophobic and hydrophobic fluoroaliphatic group, and antideposition stabilized crude oil compositions containing said compound, are disclosed.

Abstract: A device for the transdermal administration of a drug for the treatment of memory impairment comprising:(a) a drug impermeable backing layer;(b) a drug permeable rate controlling membrane sealed to one side of said backing layer as to define at least one drug reservoir compartment therebetween;(c) an adhesive layer;(d) a drug or composition thereof within said hollow drug reservoir; said drug comprising a memory improving effective amount of a compound having the formula ##STR1## wherein X.sub.1, X.sub.2, X.sub.3, X.sub.4, independently represent --H or lower alkyl;said composition comprising said drug and at least one pharmaceutically acceptable adjunct; whereby said drug is delivered in a controlled, continuous manner to a patient to which said device has been applied.

Abstract: N- and/or O-acylates, derived from carbonic acid monoesters, of desferrioxamine B of the formula ##STR1## the symbols having the following meanings: each of AA.sup.1, AA.sup.2 and AA.sup.3, independently of the others, is hydrogen, an acyl radical, referred to as Ac, of a carboxylic acid having from 1 to 24 carbon atoms, or an esterified oxycarbonyl radical referred to as Cb (acyl radical of a carbonic acid monoester) having a total of from 2 to 25 carbon atoms, andB has one of the meanings of Cb or, if at least one of the symbols AA.sup.1, AA.sup.2 and AA.sup.